This brand name is authorized in Poland
The drug SUPLIVEN contains a combination of these active pharmaceutical ingredients (APIs):
1
Chromium chloride hexahydrate
UNII KB1PCR9DMW - CHROMIC CHLORIDE
|
|
2
Copper chloride
UNII S2QG84156O - CUPRIC CHLORIDE
|
|
3
Iron(III) chloride hexahydrate
UNII S3Y25PHP1W - FERROUS CHLORIDE
|
|
4
Manganese chloride tetrahydrate
UNII QQE170PANO - MANGANESE CHLORIDE
|
Manganese is required for the synthesis of the mucopolysaccharides of cartilage, glucose utilisation, steroid biosynthesis and for the activity of pyruvate carboxylase. It is bound to arginase of the liver and activates many enzymes. |
5
Potassium iodide
UNII 1C4QK22F9J - POTASSIUM IODIDE
|
Potassium iodide is indicated as a thyroid-blocking agent to prevent the uptake of radioactive iodine, for example after a nuclear accident or during a nuclear medicine investigation before administering a radioiodinated compound, which is metabolised to iodide or which contains radioiodine impurities. |
6
Sodium fluoride
UNII 8ZYQ1474W7 - SODIUM FLUORIDE
|
Sodium fluoride is indicated for the prevention of dental caries in adolescents and adults, particularly amongst patients at risk from multiple caries (coronal and/or root caries). The primary mode of the caries preventative action of fluoride is post-eruptive, i.e topical action. Systemic fluoride supplements are believed also to act mainly topically (i.e during ingestion, via saliva). |
7
Sodium molybdate
UNII 8F2SXI1704 - SODIUM MOLYBDATE DIHYDRATE
|
|
8
Sodium selenite
UNII HIW548RQ3W - SODIUM SELENITE
|
Selenium is an essential trace element. In human, selenium compounds are glutathione peroxidase and a selenium protein P found in the plasma. Deficiency of selenium has been associated with an endemic form of cardiomyopathy, Keshan disease and with Kaschin-Beck disease, an endemic osteoarthropathy which causes a severe deformity of the joints. |
9
Zinc chloride
UNII 86Q357L16B - ZINC CHLORIDE
|
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC code | Group title | Classification |
---|---|---|
B05XA31 | Electrolytes in combination with other drugs | B Blood and blood forming organs → B05 Blood substitutes and perfusion solutions → B05X I.V. solution additives → B05XA Electrolyte solutions |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
Country: PL | Rejestru Produktรณw Leczniczych | Identifier(s): 100330349 |
ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.